Search the Newsreel

(PCRX) and the Role of Price-Sensitive Allocations

This article analyzes Pacira Biosciences Inc

Pacira BioSciences (PCRX) Is Down 7.1% After Advancing PCRX-201 Gene Therapy With Positive Phase 1 Data

Pacira BioSciences' stock (PCRX) fell 7.1% despite advancing its PCRX-201 gene therapy for knee osteoarthritis into Phase 2 following positive two-year Phase 1 data. The company also announced revised full-year revenue expectations of US$735 million to US$760 million, down from prior guidance, but reported …

Is Pacira BioSciences (PCRX) Quietly Reframing Its Non‑Opioid Strategy Around PCRX‑201 Gene Therapy?

Pacira BioSciences (NASDAQ:PCRX) Upgraded by Wall Street Zen to Strong-Buy Rating

Wall Street Zen has upgraded Pacira BioSciences (NASDAQ:PCRX) to a "strong-buy" rating from "buy," despite the broader analyst consensus remaining "Hold" with an average price target of $29.80. The company reported strong quarterly earnings, beating analyst estimates with EPS of $0.73 and revenue of …

Press Release: Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Pacira BioSciences announced inducement grants of stock options and restricted stock units (RSUs) to seven new employees. These grants, totaling 19,850 stock options and 11,000 RSUs, were made outside the company's existing equity incentive plans as an inducement material to the new hires' employment …

Here's What Analysts Are Forecasting For Pacira BioSciences, Inc. (NASDAQ:PCRX) After Its Second-Quarter Results

This article examines the latest analyst forecasts for Pacira BioSciences, Inc. (NASDAQ:PCRX) following its second-quarter results. It provides an overview of the consensus earnings estimates and how they have changed over time, along with an assessment of the company's financial performance and future prospects …

Pacira BioSciences, Inc. $PCRX Shares Purchased by Pacer Advisors Inc.

Pacer Advisors Inc. increased its stake in Pacira BioSciences, Inc. by 24.5% in the first quarter, now owning 235,427 shares. The company reported strong Q2 revenue and EPS, exceeding analyst expectations, but its 2026 revenue guidance fell below consensus. Analyst sentiment is mixed, with …

Pacira BioSciences Announces Publication of Positive Two-Year Phase 1 Data For PCRX-201 in Annals of the Rheumatic Diseases

Pacira BioSciences announced the publication of positive two-year results from its Phase 1 clinical trial for PCRX-201, an investigational gene therapy for knee osteoarthritis, in the Annals of the Rheumatic Diseases. The study found that a single intra-articular injection of PCRX-201 was well-tolerated and …

Pacira BioSciences, Inc. Stock 12‑Month Price Target Raised to $30, Implies 9% Upside

Pacira BioSciences, Inc.'s stock price target has been raised to $30 from $29.67 by 6 analysts, suggesting a 9% potential upside from its August 4 closing price. The consensus rating for PCRX remains a "Buy," with a breakdown of 3 Buys, 2 Holds, and …

Pacira BioSciences (PCRX) Stock Stumbles As Margin Erosion Clouds Profit Return

Pacira BioSciences (NASDAQ: PCRX) earns Q2 profit and sells iovera business

Pacira BioSciences (NASDAQ: PCRX) reported a profit in Q2 2026 with total revenues of $192.4 million, driven by strong sales of EXPAREL and ZILRETTA. The company also announced the divestiture of its iovera° cryoanalgesia business to Zimmer for up to $140 million, including an …

Pacira BioSciences Q2 Earnings Call Highlights

Pacira BioSciences reported a 6% increase in Q2 2026 revenue to $192.4 million, driven by strong sales of EXPAREL, ZILRETTA, and iovera°. The company highlighted expanded payer coverage for EXPAREL and progress in its pipeline, while also completing the sale of iovera° to Zimmer …

Pacira BioSciences (PCRX) Advances PCRX 201 As Its Undervalued Narrative Faces A Fresh Test

Pacira BioSciences (PCRX) has advanced its osteoarthritis gene therapy candidate, PCRX-201, to a scalable U.S. commercial manufacturing process and has begun enrolling patients in Part B of the Phase 2 ASCEND study. The company's shares are currently trading at US$26.92, which is significantly below …

Pacira Q2 Earnings & Revenues Beat, 2026 Sales Outlook Cut

Pacira BioSciences (PCRX) reported strong second-quarter 2026 results, beating analyst estimates for both earnings and revenues, driven by demand for Exparel, Zilretta, and iovera. Despite the strong performance, the company cut its 2026 sales outlook due to the divestiture of iovera, while maintaining other …

RBC Adjusts Price Target on Pacira Biosciences to $25 From $24, Maintains Sector Perform Rating

RBC has increased its price target for Pacira Biosciences (PCRX) to $25 from $24, while maintaining a Sector Perform rating on the stock. This adjustment comes shortly after Pacira BioSciences reported its Q2 2026 earnings, posting an adjusted EPS of $0.73 per share against …

Pacira Q2 2026 earnings: Revenue rises as adjusted EBITDA declines

Pacira BioSciences reported a 6% revenue increase to $192.4 million in Q2 2026, yet adjusted EBITDA declined by approximately 10% and non-GAAP net income fell 18% due to rising expenses. The company also lowered its full-year revenue guidance following the divestiture of iovera°. Despite …

Pacira BioSciences, Inc. 2026: Revenue $192.4M, EPS $0.12— 10-Q Summary

Pacira BioSciences, Inc. reported strong financial results for the 2026 quarter, with revenue of $192.4M and diluted EPS of $0.12, showing significant growth compared to the prior year. Key drivers included increased net product sales for EXPAREL and ZILRETTA, expanded reimbursement for EXPAREL, and …

Pacira BioSciences, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:PCRX) 2026-08-05

Pacira BioSciences reported a 6% increase in Q2 2026 revenue to $192.4 million, driven by strong sales of EXPAREL, ZILRETTA, and iovera°. The company highlighted expanded payer coverage for EXPAREL and progress in its pipeline, while also completing the sale of iovera° to Zimmer …

Is Pacira BioSciences Inc (PCRX) Undervalued After Q2 Earnings B

Pacira BioSciences Q2 revenue rises 6% to $192.4 million

Pacira BioSciences reported a 6% increase in Q2 2026 revenue, reaching $192.4 million, with GAAP net income of $4.7 million. The company completed the divestiture of its iovera° business and updated its full-year revenue guidance to $735 million to $760 million. Insider trading activity …

Pacira BioSciences Reports Second Quarter 2026 Financial Results

Pacira BioSciences reported solid financial results for the second quarter of 2026, with total revenue reaching $192.4 million, a 6% year-over-year increase. The company highlighted progress on its 5x30 strategy, including the divestiture of its iovera® business, expanded reimbursement for EXPAREL® by UnitedHealthcare, and …

Earnings Flash (PCRX) Pacira BioSciences, Inc. Posts Q2 Adjusted EPS $0.73 per Share, vs. FactSet Est of $0.65

Pacira BioSciences, Inc. (PCRX) announced its Q2 adjusted EPS was $0.73 per share, surpassing the FactSet estimate of $0.65. The company also reported Q2 revenue of $192.4 million, exceeding the FactSet estimate of $191.1 million, and provided updated earnings guidance for the full year …

Zimmer Biomet Deal Closes, Pacira Receives $73.6M Cash

Pacira BioSciences (NASDAQ:PCRX) Releases Quarterly Earnings Results, Beats Estimates By $0.08 EPS

Pacira (PCRX) Tops Q2 Earnings and Revenue Estimates

Pacira BioSciences Announces New National Survey Revealing the Hidden Toll of Pain on America’s Workforce

Pacira BioSciences released findings from its "Standing Strong: The Impact of Pain on America's Workforce" survey, highlighting that 85% of workers in physically demanding jobs experience pain while working, with chronic knee pain being a prevalent issue. The survey revealed significant impacts on income, …

Pacira Survey: 54% of Workers Report Pain-Related Income Loss

Pacira Biosciences Inc (PCRX) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Pacira Biosciences Inc (PCRX), detailing its current risk score, beta value, and various volatility metrics. The company ranks 49th out of 155 in the pharmaceuticals industry with a risk assessment score of 6.68 and a beta of …

Pacira enrolls first patient in Phase 2 ASCEND Part B trial of knee osteoarthritis gene therapy PCRX-201

Pacira Biosciences has enrolled the first patient in Part B of its Phase 2 ASCEND trial for PCRX-201, an investigational gene therapy for knee osteoarthritis. This milestone follows the transition to a U.S.-based commercial-scale manufacturing process. Topline results for Part A of the study, …

Pacira's knee gene therapy gets new-process drug for Phase 2

Pacira BioSciences has successfully transitioned its investigational gene therapy PCRX-201 for osteoarthritis of the knee to a scalable U.S.-based commercial manufacturing process. This allowed the enrollment of the first patient in Part B of the Phase 2 ASCEND study, while Part A enrollment concluded …

Pacira BioSciences Enrolls First Patient in Mid-stage Trial After Manufacturing Milestone

Pacira BioSciences has enrolled its first patient in a mid-stage clinical trial for PCRX-201, a gene therapy aimed at treating osteoarthritis. This milestone follows the successful transition of PCRX-201 to a scalable commercial manufacturing process, underscoring the company's progress in advancing its non-opioid pain …

Pacira BioSciences Advances PCRX-201 Development Program with Successful Transition to Scalable Commercial Manufacturing Process

Pacira BioSciences announced the successful transition of its investigational gene therapy, PCRX-201, to a scalable commercial manufacturing process, enabling the enrollment of the first patient in Part B of the Phase 2 ASCEND study. This milestone supports the company's "5x30 growth strategy" and reduces …

Pacira Biosciences Inc (PCRX) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Pacira Biosciences Inc (PCRX) focusing on its dividends and stock splits. It states that the company has not distributed any dividends over the past five years. Key financial data like market cap and P/E ratio are also presented.